Does NAD+ nasal spray work? What the evidence actually shows

The direct answer

Three facts anchor this page:

• Known: NAD+ is a coenzyme central to cellular energy metabolism, and NAD+ levels decline with age in some tissues.
• Limited evidence: intranasal NAD+ delivery is supported by preclinical animal data, not by robust human trials.
• Unknown: whether nasal NAD+ produces a measurable clinical benefit in humans for any specific condition.

What NAD+ is — the basic biology

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It plays a central role in redox reactions — the transfer of electrons that drives cellular energy production — and it is a substrate for enzymes that regulate DNA repair, cellular stress responses, and other processes. NAD+ is essential for life, and its levels decline with age in some tissues, which is why it has drawn attention as a target for longevity and cellular-health interventions.

This biology is well documented. What is important to keep separate is the next logical step: that raising or supplementing NAD+ — and doing so specifically by the nasal route — produces a measurable human health benefit. Basic NAD+ biology does not, by itself, establish that any particular NAD+ product has a clinical effect in people.

What intranasal delivery means

Intranasal delivery refers to administering a substance through the nasal mucosa. The nasal route is a real, established delivery pathway. It avoids first-pass metabolism in the liver and gastrointestinal breakdown that can reduce how much of an orally taken molecule reaches circulation, and there is a body of research on nose-to-brain transport — the idea that certain molecules may reach the central nervous system more directly through the olfactory and trigeminal nerves.

These are general properties of the nasal route, not evidence specific to NAD+. Whether a given molecule — including NAD+ — is actually absorbed, how much reaches systemic circulation, and how much (if any) reaches the brain depends on the molecule's size, stability, and formulation. A route being plausible is not the same as that route being proven effective for a particular molecule.

Current human evidence for intranasal NAD+

This is the central gap. When evaluating the human evidence, it is important not to substitute other kinds of studies for evidence about nasal NAD+ specifically.

• Animal evidence (preclinical): a 2024 study reported that intranasal NAD+ decreased brain injury in a rat model of transient focal ischemia. This is meaningful mechanistic evidence — but it is a rat model, not a human trial.
• Human IV/oral NAD+ (different route): a 2024 randomized, placebo-controlled pilot compared intravenous NR, intravenous NAD+, and oral NR in healthy adults, and a 2019 pilot administered intravenous NAD+ over several hours. These are human studies of NAD+ — but they used intravenous or oral routes, not the nose.
• Intranasal NAD+ in humans (nasal route): as of the review date, no large randomized controlled trial specifically of intranasal NAD+ was identified. A small number of case reports and preliminary reports describe intranasal NAD+ (for example, for migraine pain), but these are not controlled trials and cannot establish efficacy or safety.

Pharmacokinetic evidence — absorption and delivery

Pharmacokinetics (PK) is the study of how a substance is absorbed, distributed, metabolized, and cleared by the body. For a nasal product, the key PK questions are whether the molecule is absorbed through the nasal mucosa, how much reaches the bloodstream, and whether any reaches the brain.

As of the review date, no published human pharmacokinetic study specifically measuring the absorption of intranasal NAD+ was identified. This is an important distinction from the intravenous and oral NAD+ studies, which do measure blood levels but are not informative about what happens when NAD+ is given nasally. NAD+ is a relatively large, charged molecule, and whether it crosses the nasal mucosa and blood-brain barrier in meaningful amounts in humans is not established.

What remains unknown

An honest summary of the open questions:

• Whether intranasal NAD+ is absorbed in meaningful amounts in humans.
• Whether any absorbed NAD+ reaches the brain in humans.
• Whether nasal NAD+ produces a measurable clinical benefit for energy, cognition, longevity, or any specific condition.
• The long-term safety profile of chronic nasal NAD+ administration.

Safety considerations

Because there is no large human trial of intranasal NAD+, the long-term safety profile is not well characterized. The intravenous NAD+ pilot studies reported that NAD+ was generally well tolerated at the doses studied, but those were small, short-duration studies of a different route of administration.

A specific point to understand about compounded NAD+ products: they are prepared by compounding pharmacies and are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they reach patients. The quality, sterility, and consistency of a nasal product can vary between pharmacies, which is a meaningful consideration for a route that involves repeated mucosal application.

Claims to be skeptical of

Consumers should treat the following as unproven unless accompanied by high-quality human evidence specific to nasal NAD+:

• Anti-aging or “reverses aging” claims.
• Claims that nasal NAD+ boosts energy, improves cognition, or repairs DNA in humans.
• Claims that nasal delivery has “superior bioavailability” to IV or oral NAD+ without human PK data.
• Extrapolating results from oral NAD+ precursors, intravenous NAD+, or animal studies to the nasal route in humans.

Surfbound's clinical-review approach

Surfbound Health does not sell NAD+ nasal spray directly as a consumer product. It offers provider-reviewed NAD+ treatment, with the delivery form (including nasal spray) and strength determined by a licensed provider only after reviewing an individual's health history — not selected from a menu. Surfbound is explicit that its NAD+ is compounded and not FDA-approved.

This page's job is to describe the evidence honestly, not to promote NAD+ as a proven treatment. If you want to understand how Surfbound's NAD+ offering works — pricing, form, and the provider-review process — that information is on the dedicated page below.

References

1. 1.Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metabolism, 2018. Cell Metabolism · 2018
2. 2.Freeberg KA, et al. Dietary Supplementation With NAD+-Boosting Compounds in Humans: A Review of the Current Literature (PMC10692436). PMC / PubMed Central · 2023
3. 3.Pandya JD, et al. Intranasal delivery of mitochondria-targeted neuroprotective agents — including NAD+ — decreases brain injury in a rat model of transient focal ischemia (PMC10874030). PMC / PubMed Central · 2024
4. 4.Grant R, et al. Randomized, placebo-controlled, pilot clinical study comparing intravenous NR, intravenous NAD+, oral NR, and saline in healthy adults (preprint). medRxiv · 2024
5. 5.Grant R, Berg J, et al. Pilot study administering 750 mg intravenous NAD+ over six hours (2 mg/min) to healthy participants without adverse effects. Cited within medRxiv 2024 · 2019
6. 6.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers — compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. U.S. Food and Drug Administration · 2026

Content is provided for general health information only and does not constitute medical advice. A licensed provider determines whether any treatment is medically appropriate for you. Compounded medications are not FDA-approved.